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In the first three phases of Thromholysis and Angioplasty in 
Myocardiui Infarction (TAMI) multicenter trials, 708 pa- 
tients received intravenous recombinant issue-type plas- 
minogen activator (r&PA) and underwent detailed assess- 
ment of clinical, angiographic and ventriculographic 
outcomes. The cumulative experience und data base alford 
the opportunity to address several important questions 
regarding aggressive therapy of myocardial infarction. 
These include predictive factors of in-hospital morttlhy, 
improvement of left ventricular function and the occur- 
rence of recurrent ischemla. 
Consideration of practical issues, such as thromholytic 
therapy for patients with cardiopulmonary resuscitatior or 
previous stroke, use of coronary artery bypass surgery and 
the elfect of operator experttnce on angloplasty success 
rate, has also heen made possible. The major accnmplish- 
merits as well as the dellciencies of the current approach to 
patient management after thromholysis are reviewed, and 
the new TAM1 trials currently underway are dttussed. 
(J Am Coil Caniiol1988;12:24AJIA) 
of patients, ancillary treatment strategies and clinical out- 
comes after thrombolytic therapy. After reviewing the prln- 
cipal TAM1 findings, several of these relevant issues will be 
addressed by using the collective experience as a data base. 
In the current report, the cumulative results of the first three 
TAM1 trials will be considered, involving a total of 708 
patients. The final results of the last 50 patient study (TAMI- 
4) are not yet available. 
Principal Goals and Findings 
The primary objective and the major clinical outcomes for 
the first three TAM1 trials are summarized in Tables I and 2, 
respectively. 
TAMI- trial. The chief objective of this iniL- trial was 
to test whether immediate angioplasty after intravenous 
thrombolysis would provide addttional benefit compared 
with a deferred approach (1). Only patients with a patent 
infarct vessel and suitable coronary anatomy underwent 
random assignment. In patients randomized, the immediate 
angioplasty approach was associated with a higher mortality 
rate (4 versus I%), no improvement in predischarge ejection 
fraction (53 versus 56%), higher requirement for emergency 
coronary bypass surgery (7 versus 2%), similar frequency of 
reocclusion (II versus 13%) and increased transfusion re- 
quirement (21 versus 14%). These findings clearly demon- 
strated that after successful thrombolysis with tissue plas- 
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minogen activator, a deferred angioplasty approach was not 
inferior to the immediate strategy. 
Since the publication of the findings of the TAMI-I trial. 
there have been two additional randomized trials of n-PA 
and immediate coronary angioplasty. Despite differences m 
their study designs, in bo?h the European Cooperative Study 
(2)  and the Thrombolysis in Myocardial Infarction (TIMI)- 
IIA trial (3), similar results were obtained. Although approx- 
imately 25% of patients fail to achieve recanalization 90 min 
after infusion of rt-PA, immediate angioplasty in this group 
of patients in the TAM&I trial (4)  was associated with a poor  
clinical outcome (10.4% in-hospital mortality rate. 29% 
reocclusion rate and no imorovement in left ventricular 
function). Collectively, after-administering intravenous rt- 
recent clinical experience (8)  with a low dose combination of 
r&PA and pro-urokinase suggests hat this may be a me!hod 
to achieve synergy between two thrombolytic agents. 
In comparison with the use of “rescue” coronary angio- 
plasty after r&PA monotherapy, when combined &PA and 
urokinase failed to achieve recanalization, the results with 
angiopiasty were encouraging. Among 27 patients treated in 
this manner. onlv 4% demonstrated reocclusion. there was 
no in-hospital mortality 
low-up, there was a 5 
and from baseline to 7 day fol- 
point improvement in 
Figure 1. &NC protocol of the Thrombotysis and Angioplasty m 
Myocardlal Infraction (TAMI) Study Croup. CARG = coronary 
artery bypas\ surgery: IRA = infarct-related artery: MI = myocar- 
dial mfarctlon: PTCA = coronary angioplasty; Rx = treatment. 
ejection fraction (7). These results prompted us to perform a 
large scale randomized trial (TAMI-51, which is described in 
detail later in this report. 
TAMI- trial. The facilitation of &PA bv heparin was 
demonstrated in experimental studies (9.10). but it.remained 
uncertain whether heparin had a clinically meaningfttil :cle 
for achieving myocardial reperfusion. The TAN-3 study 
was a randomized controlled trial designed to evaluate r&PA 
and 10.000 U of heaarin versus r&PA alone. The eauivalent 
patency rate of 81% for both arms in the trial (I I) supports 
the lack of imoortance of the interaction between heoarin 
and II-PA. On this basis, we recommend not initiating 
heparin simultaneously with rt-PA, but instead to implement 
anticoagulation, if elected, at least 60 to 90 min after rt-PA 
Infusion has been started. In this way, concomitant high 
plasma levels of r&PA and heparin, which may pose an 
additive risk of bleeding, can be av0idt.i 
Predictive Fac.c zs 
In.hospitall mortality. The clinical and angiographic fac- 
tors that predict in-hospital mortality after intravenous 
thrombolytic therapy have not been well delined. Of 708 
patients in the TAMI-I to 3 trials, II predictive variables 
were examined using logistic regression as follows: age, 
gender, infarct location, history of diabetes, history of 
hvoertension, history of smoking, admission heart rate. 
systolic blood pressure, TIM1 grade of infarct vessel flow at 
9il min after therapy, number of diseased main epicardial 
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Table 2. Major Clinical Outcomes in Three Thrombolysic and Angiopla~ty in Myocardial Infarction 
(TAMI) Trialc 
TAMI-I TAMI- TAMI- OVCd 
In-hospital mortahty 
IRA patency (90 mm) 
IRA pakncv at cath 
Reoc&ion predischaise 
Emeqency CABG 
TransfuPmn (22 tJ)t 
lnlracnnial hcmonhaae 
Ill = 386)  (II = 147)  Ill = 1751 I” = 708)  
7% 4% 8% 7% 
7J7r 66’ 81% 75% 
93% wz 92% 92% 
55 of 359 (15%) 14 of 129 II 1%) Ill of 154 fIZ%l 14% 
6% 3% 6% 59i 
64 of 302 (2lrr) I7 of I25 (14%) I9 of I36 114%) I00 of 563 (IX%) 
0.5% 0.7% 1.2% 0.7% -- 
‘Include3 34 patients receivmg low dose recombmant tissue plasmmogen activator and urokin.;\e with a 3% (I3 
of 33)  p&ncy I&. :in pdlicnts nol undergoing corcnary artery bypass surgery graft (CABW. Cath = cardiac 
cathetenznrmn: IRA = mfarct-related artery. 
coronary arteries (~75% stenosis) and ejection fraction 
(Table 3). 
An important independent predictor of in-hospital sur- 
vival was TIMI-III infarct vessel flow at coronary arteriog- 
raphy. This is especially noteworthy in that TIMI-II flow, 
which denotes complete filling of the infarct-related artery 
with contrast medium, but with delayed filling or  clearance, 
was not associated with an improved survival rate. Thus, 
early and ~ornplete reperlusion was one of four key predic- 
tors of survival through hospital discharge. The other three 
independently predictive factors were the number of dis- 
eased vessels, ejection fraction and patient age. 
Left ventricular function. In a preliminary analysis of the 
major factors that have been purported to be important 
determinants of myocardial salvage, 443 patients with paired 
left ventriculographic studies were e: amined for changes in 
global and regional improvement in ejection fraction from 
baseline to 7 day follow-up study. Initially, three factors 
were examined: time to therapy from the onset of chest pain, 
sustained patency of the vessel at predischarge coronary 
angiography and baseline ejection fraclion. By linear regres- 
sion analysis, only baseline ejection fraction (p = 0.0001) 
and sustained ressel patency (p = 0.04) were independently 
predictive of improvement in cardiac function. The favor- 
able influence of persistent infarct vessel patency on recov- 
ery of myocardial function further emphasizes a major goal 
of reperfusion therapy. Surprisingly, the importance of time 
Table 3. Predictors of In-Hospital Mortality in 708 Patients 
Enrolled in the First Three Thrombolysis and Angioplasty in 
Mvocardial Infarction (TAMI) Trials 
L 
Umvanrble X’ p Value Multlvamible X’ p Value 
Age 15.7 O.lklI 5.0 0.025 
Ejectmn fraction 14.3 0.lJo1 66 0.010 
No. of dwared vewl\ II.3 0.001 9.4 0.002 
TIMI-III tlow’ 7.5 O.tM 4.3 0.038 
‘TIMIJII inlarcl vessel Row at comnlry anglography. Tlhtl = Throm. 
bolysls m Myocardldl infarction tnal. 
to therapy, which has been emphasized in nearly every 
clinical trial of myocardial reperfusion, was not found to be 
predictive. 
Baseline ejection fraction was closely associated with the 
extent of ejection fraction improvement (Table 4). Those 
patients with an ejection fraction >55% had an overall 
decrement between 3 and 5 ejection fraction percentage 
points. This observation probably reflects either more sub- 
stantial recovery in the patients with the most depressed 
initial cardiac function or  represents the “regression to the 
mean” phenomenon. The latter, an important statistical 
trend anticipated in evaluating paired studies, must be care- 
fully considered in the interpretation of data on left ventric- 
ular function. Thus, the change in ejection fraction from 
baseline to I week may not represent the best variable for 
evaluating cardirc performance after reperfusion therapy. 
Rather, the absolute ejection fraction at convalescence has 
been shown in multiple previous studies (12,131 to be a 
pivotal marker for long-term prognosis. 
Recurrent ischemia. As previously shown (14). recurrent 
ischemia after intravenous r&PA is most likely to occur 
within 24 h from the onset of therapy. The actual factors that 
predict which patients are likely to experience reinfarction. 
postinfarction angina or  reocclusion have not been eluci- 
dated. Previous studies (15.16) have suggested that the 
severity of the residual stenosis after thrombolytic therapy is 
Table 4. Importance of Baseline Left Ventricular Function to 
Change in Ejection Fraclion Over a I Week Study Period 
Time From Che~l 
Pain Onsel 10 n-PA 
Baseline EF 
545 46 lo 55 >55 
~2 h +1.5* t3.0 -5.0 
?to4h +4.0 t1.0 -3.0 
>4 h t6.0 ts.5 -3.0 
*Number m each category representr mean change in percentage points 
from acule 10 predw-barge venlnculogram. EF 7 cjeaion frdckm: n-PA = 
rccombmwil tissue-type plasminogcn acGaIor. 
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Table 5. High Risk Profile of Elderly Women m the Thromboly\l\ 
and AngioplaTty in Myocardial Infarcclon (TAM0 Toal\ 
wgge\t that. despite successful thrombolysls. elderly female 
patient; may \tdi represent an especially high risk group for 
Women Aged ,411 Other m-ho\pltal complications. This conclusion must be regarded 
265 Yean I41 P.,t,ents I%) a\ Ientdtlvc. however, owing lo subgroup analysis that was 
,n = 4% ,n = 659, p V.due not defined prospectively. 
Death 22 6 0 Illlo I Establishment of infarct vessel patency. There has been 
IRA patency (90 mm) 111 70 I I  I I I  
PTCA succcsc 
remarkable consistency in infarct vessel patency throughout 
xi x0 0 92 
Major bleedmg* 63 17 I I  MN1 
the three TAiMl trials despite changes in dose and throm- 
Trwfusion 22 U  61 27 llo(x)I 
bolyhc rsgmen? (Tab!e 2;. With rt-PA alone at either a I50 
mg dose (TAMI-I) or  1.5 mg/kg (maximal 135 mg) dose 
‘Intmcranlal or retropentoneal hemorrhage or ubwved hlcod 10% al!- 
mated at rZ U .  I R A  = mfarct-related atery. PTCA = coronary angtopla\ty 
(TAMI-3). Infarct vessel patency at 90 min was 75 and 81%. 
reqpectlvely. When 1.0 mg/kg of r&PA over 60 min was 
Practical Issues 
Stroke. Previous stroke has been accepted as an absolute 
contraindication to thrombolytic therapy. In the TAM1 tri- 
als, we did not consider a history of stroke >6 months before 
myocardial llifarction as an exclusion criterion. Of 708 
patients treated. 18 (2.5%) had a prior 06 months) stroke or  
transient ischemic attack, and none of the patients with a 
28A JhCC Vol 12. No. 6 
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Table 6. Transfusion Requiremcntc in Three TAM1 Trials 
TAMI-I TAMI- TAM1.3 Overall 
1200f3R6~3l7ir 33 or  147 I22~‘r) 53 of 175 130%) 2n6 of 708 (29vr) 
M of 302 (!I~) 17 of I25 (14’Z) 1901 136 (14’lr) IM) of 563 , IRR) 
I 8  * 3.7 I.3 t3.2 2.1 + 4.6 
w2 nmm nm/2 
Ahhrewatwn~ as m Table I. 
prior stroke had intracerebral hemorrhage or  stroke in 
follow-up. However. there is limited power in this obxrvd- 
tion of apoarent safety of thrombolytic therapy for patients 
with a rclnote history of stroke. In our  opinion, in patients 
with life-threatening myocardial infarction and a history of 
stroke, thrombolytic therapy should be considered. 
In the total cohort of 708 patients. the incidence of stroke 
hat been 2.0% (14 patients), of whom 0.7% (5 patients) 
suffered intracranial hemorrhage; in 1.3% (9 patients). the 
stroke was nonhemorrhagic and presumed to be embolic. All 
five patients with hemorrhagic stroke had at least Oue of the 
commonly accepted risk factors for intracranial hemorrhage 
(age >65 years. history of hypertension or  acute hyperten- 
sion, history oi cerebrovascular disease and use of aspirin). 
However. 80% of patients without hemorrhagic stroke had at 
least one risk factor. Thus, the most untoward effect of 
thrombolytic therapy-intracranial hemorrhage-+annot be 
readily anticipated after standard exclusion criteria have 
been applied. If all patients with such risk factors are 
excluded from thrombolytic therapy. the vast majority will 
also be excluded from the potential benefits of this therapy. 
Cardiac resuscitation. Another contraindication to the 
use of thrombolrtic therapy has been cardiopulmonary re-  
suscitation. Patients with >!!I min of resuscitation were 
deemed ineligible for entry into the TAMI studies. In the 708 
patients treated, 62 (9%) had received cardiac resuscitation 
or  defibrillation. Of these. 26 patients (4%) had chrsi LVIII- 
pression for several minutes. The patients who had had a 
cardiac arrest had a higher in-hospital mortality rate (II 
versus 6%). but there was no difference in bleeding compli- 
cation rates. In patients who had cardiopulmonary rcsusci- 
tation, there aas no occurrence of hemcnhorax or  cardiac 
tamponade. Although the potential for a type II er ror  must 
he conshiered. these data suggest that cardiac arrest and 
cardiopulmonary resuscitation of <IO min should not be 
considered a contraindication to throm’,o!ytir therapy. 
Transfusion rate. In all thrc? phases of TAMI. every 
patient underwent emergent) ;orondry angiography. In the 
presence of librinolytic therapy, invasive puncture of the 
femoral artery and vein led to a consistently high transfusion 
rate (Table 6). In the TAMI- trial in which patients received 
only 60 min of thrombolytic therapy, the transfusion require- 
ment was slightly lower. Of the two regimens used in 
TAMI-I, the briefer duration of r&PA infusion was also 
associated with a lower transfusion requirement (22). 
These data emphasize flint petformance of cardiac cnth- 
frerization in the mite phase of thromholytic therapy cor- 
ries nn increased ri.4 ofbkeding, but also point toward the 
potential for decreasing periaccess bleeding with a brief 
duration of therapy. With the overwhelming concern of 
transmitting viral infection through blood transfusion, we 
have empirically raised our  threshold for transfusion for the 
new TAM1 trials. Rather than using the previous indication 
of a hematocrit level <30 IO 35%, we recently changed the 
value to ~22% unless there is observed massive blood loss, 
hypotension or  ischemia unresponsive to crystalloid infu- 
sion. 
Coronary angioplasty SU~~CSS rate. Over the course of the 
TAMI trials, there has been a trend of avoiding immediate 
coronary angioplasty and performing the procedure on an 
elective basis (Fig. 2). This has been accompanied by an 
increase in technical success. Of the first IO0 patients, 53 
underwent immediate coronary angioplasty; in 35 (66%) the 
procedure was successful with <50% residual stenosis. The 
number of patients in the next groups of 100 enrolled, and 
the success rate was as follows: (101 to 200)  53 patients. 81% 
Figure 2. Changes in the pattern of coronary anpioplasty IPTCA) 
procedural use and timing during the first 700 patients enrolled 
(acute angioplasty [open bars]. elective angioplasty [hatched bars]). 
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success: (201 to 300)  41 patients. 90% success: (301 to 400)  
49 patients, 80% success; (401 to 500)  57 patients. 84% 
sttccess; (501 to 600)  27 patients. 89% succe& and (601 to 
700)  17 patients. 76% success. As learned in the TAN-I 
trial, in patients with successful thrombolysis. there wa\ no 
advantage of immediate angioplasty compared with deferred 
angioplasty. After the completion of the TAM&I !rial. emer- 
gency coronary angioplasty was almost totally restricted tc 
patients who were resistant to!hromboly\is. An exception to 
this application was the presence of persistent evidence of /\ 
ongoing ischemia, such as angiographtcally visible collateral 
flow, severe chest pain and marked electrocardiographic ST 
pijjE&-\ FI 
segment elevation. 
Incrensing the use of cm,qiop~~pkrst~ as WI ektiw pm e-  
Figure 3. The TAMI- protocol wrth lise of a factorial design. 
dure provided twofrmdmetttrrl odeottttt~~s. First, it allowed 
patrent\ are randomized lo a thrombolytic regime!! oi-.,ue ptasmin- 
ogen aclrvator It-PAI. urokinase [UK1 or  their combination) and to 
stabilization of the infarct-related vessel. The freshly reca- an anglographic stratsgy. Cath = cathetenzduon; other abbrcvia- 
nalized infarct-related vessel carries an apparently higher ttons as III Figure I. 
risk of complications for angioplasty, owing to only partially 
lysed fibrin, vigorous platelet aggregation and the presence 
of spontaneous plaque fissure or  rupture (l-3). Second. it 
permitted careful selection of patients with more favorable 
that in the rat model of a patent versus ligated infarct vessel, 
coronary anatomy for angioplasty (I ). The improved success 
there was less tendency for ventricular aneurysm formation 
rate may also be explained by progression along the learning 
and improved healing by histologic variables, even thoogh 
curve (23,24), but the operators had previously performed a 
comr’-te infarction had been created. In the Western Wash- 
high requisite number of emergency coronary angioplasty 
ington trial of intracoronary streptokinase (26). patients with 
procedures before initiation of the first trial (I). 
restoration of vessel patency had a substantially improved 
tong-term prognosis compared wi!h !hose wi!h partial or  no 
reperfuston. without any demonstrable improvement in left 
New TAMI Trials ventricular function. Recently. Brugada et al. (27)  showed a 
TAMI-5. Two important lingering questions in acute lower threshold for inducible ventricular tachycardia among 
intervention are: I) what is the best rhrombolytic regimen; 
patients with an occluded versus a patent Infarct vessel. In 
and 2)  should emergency coronary angiography and. if 
the large scale ISIS-2 trial (28)  of >17,000 patients who 
necessary, “rescue’* coronary angioplasty be performed? received intravenous streptokinase or  placebo up to 24 h 
The TAMI-J trial employs a factorial design of these two after symptom onset, a significant survival advantage was 
questions (Fig. 3). Patients are randomized to one of three 
confirmed for patients treated with streptokinase even I2 to 
thrombolytic regimens and one of two angiographic strate- 24 h after the onset of chest pain. 
gies. The thrombolytic regimens include rt-PA (IO0 mg over 
These findings have prompted us to conduct a trial of 
3 h), rt-PA plus urokinase (I mg/kg and I.5 million units, thrombolysis and angioplasty for patients who present 6 to 
respectively, over 60 min) or  urokinase (3.0 million units 24 h after symptom onset. To test the “open vessel hypoth- 
over I h). The angiographic strategies involve either emer- esis.” in TAMl-6 (Fig. 4). intravenous @PA or  placebo will 
gency coronary angiography with “rescue” coronary angio- be administered to 200 patients. Coronary angiography will 
plasty if the infarct-related artery remains occluded at 90 min be performed within 24 h from study drug initiation. In the 
of thrombolytic therapy or  no cardiac catheterization until 7  patients with an occluded infarct vessel, a  second random- 
days. In this trial, left ventricular function is the primary end ization will be made to either angioplasty or  no angioplasty. 
point: the planned enrollment is 600 patients and completion The study’s primary end point is patency of the infarct 
is anticipated in early 1989. The results are expected IO vessel. However. left ventricular function at baseline and at 
confirm or  disprove the encouraging TAMI- results for 3 months will be serially evaluated. Cumulative experience 
rescue angioplasty (7)  and should have practical application with r&PA (29)  has shown this agent to be highly efficacious 
for early triage decisions for patients in a community hospi- independent of time, with consistent patency rates of 65 to 
tal without cardidc catheterization facilities. 75% as long as 9 h from the onset of symptoms. Because 
TAME-B. Several experimental studies suggest that es- approximately 25 to 35% of patients with myocardia! infarc- 
tablishment of an “open” infarct-related artery confers a tion present 6 to 24 h after symptom onset (30-32). the 
better outcome regardless of whether there has been any results of this trial mry extend the therapeutic benefit to a 
myocardial salvage. Hochman and Choo (25)  demonstrated significant proportion of patients. 
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Figure 4. The TAMI- prolocol. MUGA = gated blood pool scinti- 
graphic ejection fraction: other abbreviations as in Figures t and 3. 
Major Deficiencies of Acute Intervention 
Deficiencies. Despite recent advances and enhanced un- 
derstanding of the benefits of aggressive therapy for evolving 
myocardial infarction, there remain several key deficiencies 
(Table 7). First, as demonstrated in the TAMI studies and 
other investigations (l-3,7,1 1). there is currently a pharma- 
cologic intervention plateau-at approximately 75%-with 
respect to acute infarct vessel patency. Second, the time to 
recanalization is prolonged, with an average of 45 to 50 min. 
even with the highest doses of thrombolytic therapy (33). 
Third, the occurrence and unpredictability of serious bleed- 
ing episodes and recurrent ischemic events, as discussed 
earlier in this report, are important disadvantages of such 
therapy. Fourth, the inability to accurately detect reperfu- 
sion with clinical noninvasive indexes (34) makes prefer- 
ential triage in the acute phase quite difficult withou: per- 
forming coronary angiography. Fifth, although early 
thrombolytic intervention has been shown to enhance sur- 
vival, improve cardiac function and lessen infarct size, many 
patients are not eligible by current criteria. Recent studies 
(3tL32) that have considered eligibility suggest that only 14 
to 35% of patients are actually candidates. Finally, left 
ventricular functional recovery has not been particularly 
substantial in most studies (l-3,35). For example, in patients 
randomly assigned to delayed elective coronary angioplasty 
in the TAMI-I trial, only a 1.3 percentage point improve- 
ment in ejection fraction was demonstrated from baseline to 
day 7 (I). 
Approaches to address deficiencies. There are many ap- 
proaches that are currently being developed to address these 
deficiencies. Newer, enhanced clot-selective agents have the 
potential to lyse coronary artery fibrin more rapidly (36). 
Either alone or in combination with potent platelet inhibi- 
tors, such as the glycoprotein IIA-BIB platelet antibody 
(37). there is the potential to “break through” the 75% 
ceiling. Similarty, improved platelet antagonism may reduce 
recurrent ischemic events. Methods to eliminate intracranial 
hemorrhage or other serious bleeding episodes have not 
been developed, although the concept of “organ-selective” 
thrombolysis has been discussed. There are several potential 
serologic markers, such as creatine kinase isoforms or 
myoglobin, that may be useful for rapid diagnosis of reper- 
fusion. Pharmacologic methods to enhance cardiac func- 
tional recovery are under study with agents to limit reper- 
fusion injury, such as superoxide dismutase. Use of 
thrombolytic therapy will be increasingly extended to pa- 
tients presenting >6 h after symptom onset if this proves to 
be effective. Although the TAM1 studies have tackled a few 
specific questions, there are multiple significant limitations 
of our current approach, leaving room for considerable 
further clinical investigation in this area. 
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